<DOC>
	<DOCNO>NCT01966003</DOCNO>
	<brief_summary>The purpose research study compare effectiveness safety ABP 215 bevacizumab men woman advance non-small cell lung cancer .</brief_summary>
	<brief_title>Efficacy Safety Study ABP 215 Compared With Bevacizumab Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm nonsquamous nonsmall cell lung cancer Subjects must initiate firstline carboplatin/paclitaxel chemotherapy within 8 day randomization expect receive least 4 cycle chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Small cell lung cancer ( SCLC ) mix SCLC NSCLC Central nervous system ( CNS ) metastases Malignancy NSCLC Palliative radiotherapy bone lesion inside thorax Prior radiotherapy bone marrow Known positive hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Life expectancy &lt; 6 month Woman childbearing potential pregnant breast feed consent use highly effective method birth control treatment additional 6 month last administration protocol specified treatment Man partner childbearing potential consent use highly effective method birth control treatment additional 6 month last administration protocol specified treatment Subject know sensitivity product administer study , include mammalian cell derive drug product Other inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>